Research of SORD-CMT Natural History and Epalrestat Treatment

Inclusion Criteria: * Genetically confirmed SORD-CMT2 patients. * Male or non-pregnant, non-lactating female patients, aged \> 14 and ≤ 50 years old. * Rule out secondary peripheral neuropathy (e.g., diabetic peripheral neuropathy) * Voluntarily participate in clinical trials, sign informed consent, and be able to understand and abide by research procedures. P.S. Patients who have a strong willingness to treat and voluntarily purchase epalrestat for treatment (50mg, three times a day) are included in the treatment group. Exclusion Criteria: * Presence of any other cause of peripheral neuropathy. * Subjects with other neurological disorders affecting the evaluation of study treatment. * History of clinically significant unstable medical disease that may cause harm to subjects participating in this study within the past 1 year. * Patients with major trauma or extremity surgery before enrollment or planned for extremity surgery before completion of follow-up. * Patients with previous bilateral ankle stabilization surgery. * Patients who were treated with other related drugs in the 3 months before enrollment. * Have any history of drug abuse; have a history of alcohol dependence in the past 3 months. * Subjects who are positive for syphilis antibody and HIV antibody. * Subjects whose chest X-ray and B-ultrasound show tumors. * Patients with poor compliance and unable to complete the study follow-up. * Patients who do not agree to participate in the study. * Other factors are not suitable for inclusion.